• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

sFlt-1/PlGF 比值在<38、38-85 和>85 范围内与围产结局的比较。

The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.

机构信息

Department of Gynecology and Obstetrics, Pomeranian Medical University, Clinical Hospital nr 2, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.

Department of Gynecology and Obstetrics, Pomeranian Medical University, Szczecin, Poland.

出版信息

J Perinat Med. 2019 Sep 25;47(7):732-740. doi: 10.1515/jpm-2019-0019.

DOI:10.1515/jpm-2019-0019
PMID:31339858
Abstract

Background Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are used as markers of preeclampsia. The aim of this paper was to assess the correlations between the sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets and perinatal outcomes in pregnancies that require determination of these markers. Methods A total of 927 pregnant patients between 18 and 41 weeks' gestation suspected of or confirmed with any form of placental insufficiency (preeclampsia, intrauterine growth restriction [IUGR], gestational hypertension, HELLP syndrome, placental abruption) were included in the study. In each of the patients, the sFlt-1/PlGF ratio was calculated. Patients were divided into three groups according to the sFlt-1/PlGF ratio brackets of <38, 38-85 and >85. Results Significantly worse perinatal outcomes were found in the sFlt-1/PlGF >85 group, primarily with lower cord blood pH, neonatal birth weight and shorter duration of gestation. Statistically significant correlations between the values of these markers and the abovementioned perinatal effects were found. Conclusion An sFlt-1/PlGF ratio value of >85 suggests that either preeclampsia or one of the other placental insufficiency forms may occur, which is associated with lower cord blood pH, newborn weight and earlier delivery. Determining the disordered angiogenesis markers and calculating the sFlt-1/PlGF ratio in pregnancies complicated by placental insufficiency may lead to better diagnosis, therapeutic decisions and better perinatal outcomes.

摘要

背景

可溶性血管内皮生长因子受体 1(sFlt-1)和胎盘生长因子(PlGF)可作为子痫前期的标志物。本文旨在评估 38 周之前、38-85 周之间和 85 周之后这三个不同 sFlt-1/PlGF 比值范围内的比值与需要确定这些标志物的妊娠围产期结局之间的相关性。

方法

共纳入 927 例 18-41 孕周疑似或确诊存在胎盘功能不全(子痫前期、胎儿宫内生长受限、妊娠期高血压、HELLP 综合征、胎盘早剥)的孕妇,计算每位患者的 sFlt-1/PlGF 比值,并根据 sFlt-1/PlGF 比值范围将患者分为<38、38-85 和>85 三个组。

结果

sFlt-1/PlGF>85 组的围产结局明显较差,主要表现为脐血 pH 值较低、新生儿出生体重较轻和妊娠时间较短。这些标志物的数值与上述围产结局之间存在显著的相关性。

结论

sFlt-1/PlGF 比值>85 提示可能存在子痫前期或其他一种胎盘功能不全形式,与脐血 pH 值较低、新生儿体重较轻和分娩较早相关。在胎盘功能不全的妊娠中检测血管生成标志物紊乱并计算 sFlt-1/PlGF 比值,可能有助于更好地诊断、制定治疗决策并改善围产结局。

相似文献

1
The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.sFlt-1/PlGF 比值在<38、38-85 和>85 范围内与围产结局的比较。
J Perinat Med. 2019 Sep 25;47(7):732-740. doi: 10.1515/jpm-2019-0019.
2
An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia.可溶性血管内皮生长因子受体-1(sFlt-1)与胎盘生长因子(PlGF)的比值为655时,并非预测子痫前期女性围产期结局的可靠临界值。
Pregnancy Hypertens. 2018 Jan;11:54-60. doi: 10.1016/j.preghy.2018.01.001. Epub 2018 Jan 2.
3
Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.可溶性 fms 样酪氨酸激酶与胎盘生长因子比值在不同时期的胎儿生长受限及小于胎龄儿中的变化。
Acta Obstet Gynecol Scand. 2021 Jan;100(1):119-128. doi: 10.1111/aogs.13978. Epub 2020 Sep 14.
4
The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.可溶性fms样酪氨酸激酶-1(sFLT-1)与胎盘生长因子(PIGF)的比值作为子痫前期严重程度的可能指标——单机构经验
Med Glas (Zenica). 2019 Feb 1;16(1):53-59. doi: 10.17392/994-19.
5
Does a sFlt-1/PlGF ratio result > 655 before 34 weeks' gestation necessitate preterm delivery within 2 days? A retrospective observational study.在 34 周妊娠前 sFlt-1/PlGF 比值是否大于 655 是否需要在 2 天内进行早产?一项回顾性观察研究。
J Matern Fetal Neonatal Med. 2024 Dec;37(1):2371047. doi: 10.1080/14767058.2024.2371047. Epub 2024 Jun 26.
6
Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.可溶性 fms 样酪氨酸激酶-1 和胎盘生长因子在疑似或确诊子痫前期孕妇妊娠期间和产后的动力学变化。
Ultrasound Obstet Gynecol. 2018 Jun;51(6):751-757. doi: 10.1002/uog.17547. Epub 2018 May 6.
7
Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.sFlt-1/PlGF 比值和胎儿-母亲多普勒血流检测预测晚发型子痫前期不良围生结局的作用。
Arch Gynecol Obstet. 2020 Feb;301(2):375-385. doi: 10.1007/s00404-019-05365-9. Epub 2019 Nov 16.
8
Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.胎盘、胎儿及母体心血管标志物在预测疑似或确诊子痫前期女性不良结局中的作用
Ultrasound Obstet Gynecol. 2022 May;59(5):596-605. doi: 10.1002/uog.24851.
9
Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study.临床常规中 sFlt-1(可溶性 fms 样酪氨酸激酶 1)/PlGF(胎盘生长因子)比值预测子痫前期相关不良结局:一项真实世界研究。
Hypertension. 2021 Feb;77(2):461-471. doi: 10.1161/HYPERTENSIONAHA.120.15146. Epub 2020 Dec 7.
10
Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.sFlt-1(可溶性 fms-样酪氨酸激酶 1)/PlGF(胎盘生长因子)比值极高与母婴围产结局的相关性。
J Am Heart Assoc. 2020 Apr 7;9(7):e015548. doi: 10.1161/JAHA.119.015548. Epub 2020 Apr 4.

引用本文的文献

1
Angiogenic Biomarkers: Are They Good Tools to Predict Perinatal Outcomes in Hypertensive Disorders of Pregnancy? A Retrospective Cohort Study.血管生成生物标志物:它们是预测妊娠高血压疾病围产期结局的好工具吗?一项回顾性队列研究。
Diagnostics (Basel). 2025 Mar 21;15(7):799. doi: 10.3390/diagnostics15070799.
2
Maternal Serum Angiogenic Profile and Its Correlations with Ultrasound Parameters and Perinatal Results in Normotensive and Preeclamptic Pregnancies Complicated by Fetal Growth Restriction.正常血压和子痫前期合并胎儿生长受限妊娠中母体血清血管生成谱及其与超声参数和围产期结局的相关性
J Clin Med. 2023 Jun 26;12(13):4281. doi: 10.3390/jcm12134281.
3
The sFlt-1/PlGF Ratio in Pregnant Patients Affected by COVID-19.
新冠病毒感染孕妇的可溶性血管内皮生长因子受体-1/胎盘生长因子比值
J Clin Med. 2023 Jan 29;12(3):1059. doi: 10.3390/jcm12031059.
4
Birth Weight < 3rd Percentile Prediction Using Additional Biochemical Markers-The Uric Acid Level and Angiogenesis Markers (sFlt-1, PlGF)-An Exploratory Study.利用生化标志物尿酸水平和血管生成标志物(sFlt-1、PlGF)预测出生体重<第 3 百分位——一项探索性研究。
Int J Environ Res Public Health. 2022 Nov 16;19(22):15059. doi: 10.3390/ijerph192215059.
5
Adverse Neonatal Outcome of Pregnancies Complicated by Preeclampsia.子痫前期合并妊娠的不良新生儿结局
Biomedicines. 2022 Aug 22;10(8):2048. doi: 10.3390/biomedicines10082048.
6
The Impact of Increased Maternal sFlt-1/PlGF Ratio on Motor Outcome of Preterm Infants.母血清 sFlt-1/PlGF 比值升高对早产儿运动结局的影响。
Front Endocrinol (Lausanne). 2022 Jun 30;13:913514. doi: 10.3389/fendo.2022.913514. eCollection 2022.
7
sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates.可溶性血管内皮生长因子受体-1/胎盘生长因子比值预测小于胎龄儿新生儿短期结局的研究
Children (Basel). 2021 Aug 23;8(8):718. doi: 10.3390/children8080718.
8
Prediction of Adverse Pregnancy Outcome Related to Placental Dysfunction Using the sFlt-1/PlGF Ratio: A Narrative Review.使用sFlt-1/PlGF比值预测与胎盘功能障碍相关的不良妊娠结局:一项叙述性综述
Geburtshilfe Frauenheilkd. 2021 Aug;81(8):948-954. doi: 10.1055/a-1403-2576. Epub 2021 Aug 9.
9
Standard care informed by the result of a placental growth factor blood test versus standard care alone in women with reduced fetal movement at or after 36 weeks' gestation: a pilot randomised controlled trial.在妊娠36周及以后出现胎动减少的女性中,根据胎盘生长因子血液检测结果提供的标准护理与单纯标准护理的对比:一项试点随机对照试验。
Pilot Feasibility Stud. 2020 Feb 13;6:23. doi: 10.1186/s40814-020-0561-z. eCollection 2020.
10
Maternal circulating concentrations of soluble Fas and Elabela in early- and late-onset preeclampsia.早发型和晚发型子痫前期孕妇母血中可溶性 Fas 和 Elabela 的浓度。
J Matern Fetal Neonatal Med. 2022 Jan;35(2):316-329. doi: 10.1080/14767058.2020.1716720. Epub 2020 Feb 2.